	Outcomes of Neoadjuvant Radiotherapy Followed by Robotic Radical Prostatectomy in High-Risk Locally Advanced Prostate Cancer: A Prospective Pilot Study. Ann Surg Oncol Tseng CS, Chang CK, Li HJ, Liu YT, Huang SW, Huang CY, Cheng JC. PMID: 42423939 [PubMed - as supplied by publisher]
	Association Between Psoriasis and Prostate Cancer Risk in Men: A Retrospective Cohort Study. J Epidemiol Glob Health Lai SW, Liao KF. PMID: 42423818 [PubMed - as supplied by publisher]
	[Geriatric assessments and their practical application in uro-oncology : How do we decide on prostate cancer treatment in an age-appropriate way?]. Urologie Fiebig C, Manseck A, Stein J, Piotrowski A, Fröhner M, Umbehr M, Butea-Bocu M, Wiedemann A. PMID: 42423720 [PubMed - as supplied by publisher]
	Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum. J Urol Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Caamaño AG, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. PMID: 42423152 [PubMed - in process]
	A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045. Sci Prog Chen N, Cai J, Feng J, He Y, Xu D. PMID: 42423065 [PubMed - indexed for MEDLINE]
	Overview of clear cell renal cell carcinoma: from mechanisms to clinical. Front Med (Lausanne) Yang H, Zhang X, Ji Q, Sheng X. PMID: 42422841 [PubMed]
	Late Renal Cell Carcinoma Metastasis Mimicking an Arteriovenous Malformation in the Parotid and Masseter Region: A Diagnostic Pitfall. Cureus Huerta Diaz LA, Lopez Alanis BA, Ortiz Villeda FE, Treviño Lozano MA, Muñoz-Maldonado GE. PMID: 42422606 [PubMed]
	Magnetic Resonance Imaging-based Prostate Cancer Diagnosis Using Principal Component Analysis and Machine Learning Algorithms. J Med Phys Samta N, Sureka CS, Sarasanandarajah S, Jeevanram RK. PMID: 42422134 [PubMed]
	Navigating Recurrence in Clear Cell Renal Cell Carcinoma after Adjuvant Immunotherapy. J Kidney Cancer VHL Sunny G, Ravichandran S, Patnaik A, Yadav R. PMID: 42422057 [PubMed]
	Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy. Front Oncol Liu Z, Wu J, Lu Q, Li Y, Yang Y. PMID: 42421680 [PubMed]
	Keratin 17 immunocytochemistry in urine cytology for urothelial carcinoma detection: Diagnostic performance and interobserver agreement in a prospective real-world cohort. Cancer Cytopathol Barth G, Koch S, Ecke TH. PMID: 42421607 [PubMed - indexed for MEDLINE]
	Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer. Int J Urol Elting L, Almohtasib J, Francisco IFS, Pérez-Londoño A, Al-Faouri R, Kaplan I, Aronovitz J, Mehta P, Gershman B, Olumi AF, Aghdam N. PMID: 42421489 [PubMed - indexed for MEDLINE]
	Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'? J Pathol Schepisi G, Torresan I, Giunta EF, Bleve S, Brighi N, Tassinari E, Zanuccoli S, Cursano MC, Lolli C. PMID: 42420213 [PubMed - as supplied by publisher]
	Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making. Eur Urol Oncol Thibault C, Blons H, Allory Y, Harba A, Roumiguié M, Seisen T, Marcq G, Bajeot AS, Leon P, Masson-Lecomte A, Pradère B, Xylinas E, Prost D, Gabriel PE, Laurent-Puig P, Rouprêt M, Audenet F, Cancer Committee of The French Association of Urology (CC-AFU). PMID: 42420157 [PubMed - as supplied by publisher]
	MRI-based Response Assessment of Neoadjuvant Systemic Immunotherapy in Muscle-invasive Bladder Cancer: An Analysis of Inter-radiologist Variability and Diagnostic Accuracy in three Prospective Clinical Trials. Eur Urol Oncol Greidanus J, van Dijk-de Haan MC, Messina A, Calareso G, Bruining A, Westerink B, Dehghanpour A, Tissier R, van Dorp J, Stockem CF, Pipinikas C, Mertens LS, van der Poel HG, Beets-Tan RGH, van Rhijn BWG, Giannatempo P, van der Heijden MS, Trebeschi S, Boellaard TN. PMID: 42420156 [PubMed - as supplied by publisher]
	Development and acceptability of gist-based decision aids for prostate and breast cancer screening: a two-phase qualitative interview study in an online setting. BMJ Open Nalavenkata S, Bergengren O, Lynch K, Emard N, Austria M, Martin S, Ogbennaya G, Dualeh K, Stevanovic K, Patel MI, Gonsky J, Vickers A, Fagerlin A, Hamilton JG, Hay JL, Carlsson S. PMID: 42419884 [PubMed - indexed for MEDLINE]
	(Cost-)effectiveness of focal therapy versus radical therapy (standard of care) in the treatment of men with intermediate-risk prostate cancer: study protocol for the ENFORCE focal randomised controlled trial. BMJ Open Te Molder LPW, Sedelaar JPM, Bomers JGR, Boomsma MF, de Haan TD, van Melick HHE, Meijerink MR, Beerlage HP, van Aubel O, Collette ER, Grutters JPC, Hannink G, Rovers MM, Fütterer JJ, ENFORCE Focal consortium. PMID: 42419881 [PubMed - indexed for MEDLINE]
	Advances in systemic therapies for advanced prostate cancer. BMJ Childs DS, Hahn AW, Ravi P, Orme JJ. PMID: 42419784 [PubMed - indexed for MEDLINE]
	Genetics and Screening in Prostate Cancer. Surg Clin North Am Partuzo JGR, Mora-Garijo B, Hwang J. PMID: 42419315 [PubMed - indexed for MEDLINE]
	Identification and verification of immunogenic cell death-related signatures derived from bone metastasis of prostate cancer based on multi-omics and machine learning algorithms. Comput Biol Chem Ma W, Mei W, Guang L, Yang Q, Xu M, Zhou H. PMID: 42419189 [PubMed - as supplied by publisher]

Articles 1 - 20 / 179873

Page 1 of 8994



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy